KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cvs Health (CVS) Net Income towards Common Stockholders (2016 - 2025)

Cvs Health's Net Income towards Common Stockholders history spans 17 years, with the latest figure at $2.9 billion for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 80.1% year-over-year to $2.9 billion, compared with a TTM value of $1.7 billion through Dec 2025, down 62.32%, and an annual FY2025 reading of $1.7 billion, down 62.32% over the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $2.9 billion at Cvs Health, up from -$4.0 billion in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $3.0 billion in Q2 2022, with the low at -$4.0 billion in Q3 2025.
  • Average Net Income towards Common Stockholders over 5 years is $1.3 billion, with a median of $1.8 billion recorded in 2021.
  • Year-over-year, Net Income towards Common Stockholders skyrocketed 166.64% in 2023 and then crashed 5719.72% in 2025.
  • Tracing CVS's Net Income towards Common Stockholders over 5 years: stood at $1.4 billion in 2021, then skyrocketed by 68.13% to $2.3 billion in 2022, then fell by 12.22% to $2.0 billion in 2023, then decreased by 20.71% to $1.6 billion in 2024, then soared by 80.1% to $2.9 billion in 2025.
  • Per Business Quant, the three most recent readings for CVS's Net Income towards Common Stockholders are $2.9 billion (Q4 2025), -$4.0 billion (Q3 2025), and $1.0 billion (Q2 2025).